Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aromatic-cationic peptides and methods for using same

A subject and surgical technique, applied in the direction of peptides, tripeptide components, tetrapeptide components, etc.

Inactive Publication Date: 2014-08-13
MAYO FOUND FOR MEDICAL EDUCATION & RES +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, successful restoration of renal artery patency does not necessarily translate into restoration of tissue perfusion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aromatic-cationic peptides and methods for using same
  • Aromatic-cationic peptides and methods for using same
  • Aromatic-cationic peptides and methods for using same

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0162] II. Preparation of Aromatic-Cationic Peptides of the Present Technology

[0163] The aromatic-cationic peptides of the present technology are water-soluble and highly polar. Despite these properties, the peptide can easily penetrate cell membranes. The aromatic-cationic peptide typically comprises a minimum of 3 amino acids or a minimum of 4 amino acids covalently linked by peptide bonds. The maximum number of amino acids present in the aromatic-cationic peptide is about 20 amino acids covalently linked by peptide bonds. Suitably, the maximum number of amino acids is about 12, more preferably about 9 and most preferably about 6.

[0164] The amino acid of the aromatic-cationic peptide can be any amino acid. The term "amino acid" as used herein is intended to refer to any organic molecule comprising at least one amino group and at least one carboxyl group. Typically, at least one amino group is alpha to the carboxyl group. The amino acid may be naturally occurring...

Embodiment 1

[0276] Example 1 by using D-Arg-2', 6'-Dmt-Lys-Phe-NH 2 to alleviate porcine renal atherosclerosis Renal damage after percutaneous transluminal renal angioplasty (PTRA) in arterial stenosis-like stenosis (ARAS) hurt.

[0277] A. Introduction

[0278] This example confirms that the aromatic cationic peptide D-Arg-2', 6'-Dmt-Lys-Phe-NH 2 Use in the prevention and treatment of renal injury associated with renal atherosclerotic arterial stenosis (ARAS). According to the methods of the invention, animal subjects are subjected to ARAS for a period of time, followed by renal revascularization by percutaneous transluminal renal angioplasty (PTRA). The aromatic-cationic peptide is administered to the subject in conjunction with PTRA, including for defined periods of time before and after revascularization surgery. Control animals received either an infusion or an infusion of control vehicle alone. Various aspects of renal function were improved in subjects receiving the p...

Embodiment 2

[0355] Example 2 by using D-Arg-2', 6'-Dmt-Lys-Phe-NH 2 to alleviate atherosclerosis in humans Renal damage after percutaneous transluminal renal angioplasty (ARAS) in sclerotic renal artery stenosis (ARAS) hurt

[0356] A. Overview

[0357] This example will confirm that the aromatic cationic peptide D-Arg-2', 6'-Dmt-Lys-Phe-NH 2 Use in the prevention and treatment of renal injury associated with renal atherosclerotic artery stenosis (ARAS) in humans. According to the methods of the invention, a human subject with ARAS undergoes renal revascularization by percutaneous transluminal renal angioplasty (PTRA). The subject is administered the aromatic-cationic peptide conjugated to PTRA, including for defined periods of time before and after revascularization surgery. Control subjects either received no infusion or received an infusion of control vehicle alone. Multiple aspects of renal function are expected to be improved in subjects receiving the peptide (compared ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 61 / 540,910, filed September 29, 2011, U.S. Provisional Application No. 61 / 596,455, filed February 8, 2012, U.S. Provisional Application No. 61 / 558,177, filed November 10, 2011 , US Provisional Application No. 61 / 642,282, filed May 3, 2012, and US Provisional Application No. 61 / 681,444, filed August 9, 2012, which are hereby incorporated by reference in their entirety. technical field [0003] The present technology generally relates to compositions and methods for preventing or treating renal ischemia / reperfusion tissue damage. Specifically, embodiments of the present technology relate to administering an effective amount of an aromatic-cationic peptide to prevent or treat ischemia / reperfusion injury associated with restoration of renal artery patency for the treatment of renal artery stenosis and for For the long-term treatment of atherosclerotic renovascular dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/04C07K5/00A61K38/00
CPCC07K5/0817A61K38/06A61K45/06A61K38/07A61P13/12A61P7/02A61P9/04A61P9/10A61P9/12A61K2300/00
Inventor D·特拉维斯·威尔逊利拉奇·O·莱尔曼斯蒂芬·C·特克斯托尔
Owner MAYO FOUND FOR MEDICAL EDUCATION & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com